Synthetic polyribonucleotides: current role and potential use in oncological practice

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Polyadenylic-polyuridylic acid (PAPU) is known to modulate immunological cells and functions.
• PAPU has demonstrated potential in enhancing both cellular and humoral immunity.
• Specifically, it shows promise in bolstering anti-cancer host defenses in preclinical and clinical studies.

Purpose of the Study:

• To review the current status of Polyadenylic-polyuridylic acid (PAPU) in cancer therapy.
• To evaluate the beneficial adjuvant effects of PAPU in clinical trials.
• To identify priority areas for future research regarding PAPU's therapeutic applications.

Main Methods:

• Review of existing literature on Polyadenylic-polyuridylic acid (PAPU).
• Analysis of clinical trial data, particularly for breast and stomach cancers.
• Assessment of reported side effects and survival data.

Main Results:

• PAPU demonstrated a beneficial adjuvant effect in limited clinical trials, prolonging disease-free and overall survival.
• Reported side effects associated with PAPU administration were minimal.
• Evidence suggests PAPU enhances anti-cancer host defenses in animals and humans.

Conclusions:

• Polyadenylic-polyuridylic acid (PAPU) warrants further investigation as an immunotherapeutic agent in oncology.
• The precise mechanism of action for PAPU requires elucidation.
• Establishing optimal therapeutic regimens and further clinical evaluation are crucial next steps.